1. Home
  2. INSM vs CTSH Comparison

INSM vs CTSH Comparison

Compare INSM & CTSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • CTSH
  • Stock Information
  • Founded
  • INSM 1988
  • CTSH 1994
  • Country
  • INSM United States
  • CTSH United States
  • Employees
  • INSM N/A
  • CTSH N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • CTSH EDP Services
  • Sector
  • INSM Health Care
  • CTSH Technology
  • Exchange
  • INSM Nasdaq
  • CTSH Nasdaq
  • Market Cap
  • INSM 29.0B
  • CTSH 34.1B
  • IPO Year
  • INSM 2000
  • CTSH 1998
  • Fundamental
  • Price
  • INSM $162.43
  • CTSH $68.44
  • Analyst Decision
  • INSM Strong Buy
  • CTSH Buy
  • Analyst Count
  • INSM 19
  • CTSH 14
  • Target Price
  • INSM $152.71
  • CTSH $87.15
  • AVG Volume (30 Days)
  • INSM 2.2M
  • CTSH 4.4M
  • Earning Date
  • INSM 10-30-2025
  • CTSH 10-29-2025
  • Dividend Yield
  • INSM N/A
  • CTSH 1.81%
  • EPS Growth
  • INSM N/A
  • CTSH 12.27
  • EPS
  • INSM N/A
  • CTSH 4.93
  • Revenue
  • INSM $398,105,000.00
  • CTSH $20,486,000,000.00
  • Revenue This Year
  • INSM $32.44
  • CTSH $8.28
  • Revenue Next Year
  • INSM $123.99
  • CTSH $4.71
  • P/E Ratio
  • INSM N/A
  • CTSH $13.88
  • Revenue Growth
  • INSM 21.15
  • CTSH 6.34
  • 52 Week Low
  • INSM $60.40
  • CTSH $65.17
  • 52 Week High
  • INSM $163.22
  • CTSH $90.82
  • Technical
  • Relative Strength Index (RSI)
  • INSM 80.62
  • CTSH 48.45
  • Support Level
  • INSM $156.87
  • CTSH $67.60
  • Resistance Level
  • INSM $163.22
  • CTSH $67.61
  • Average True Range (ATR)
  • INSM 4.29
  • CTSH 1.15
  • MACD
  • INSM 0.73
  • CTSH 0.26
  • Stochastic Oscillator
  • INSM 94.51
  • CTSH 87.18

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About CTSH Cognizant Technology Solutions Corporation

Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 350,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.

Share on Social Networks: